New combo therapy offers hope for advanced cervical cancer patients
NCT ID NCT07472153
First seen Mar 16, 2026 · Last updated May 16, 2026 · Updated 7 times
Summary
This study tests a combination of immunotherapy drugs (PD-1/PD-L1 inhibitors) with chemotherapy, with or without another drug called bevacizumab, in 120 adults with cervical cancer that has spread, persisted, or returned. The goal is to see if this approach helps patients live longer and shrinks tumors. Participants must be between 18 and 75 years old and have a confirmed diagnosis.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CERVICAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
N.N. Alexandrov National Caner Centre
RECRUITINGMinsk, Lesnoy, 223040, Belarus
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.